Peroxisome proliferator-activated receptors in atherosclerosis and inflammation - An update

被引:31
作者
Elangbam, CS [1 ]
Tyler, RD [1 ]
Lightfoot, RM [1 ]
机构
[1] Glaxo Wellcome Inc, Dept Pathol, Res Triangle Pk, NC 27709 USA
关键词
adipocyte differentiation; atherosclerosis; chemokines; cytokines; inflammation; nuclear receptors; peroxisome proliferator-activated receptors;
D O I
10.1080/019262301317052495
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor subfamily of transcription factors with pleiotropic effects on intra- and extracellular lipid metabolism, glucose homeostasis, cell proliferation, control of inflammation, and atherosclerosis. Three PPARs, namely alpha, delta, and gamma have been identified with distinct tissue distribution patterns and metabolic functions. PPAR-alpha is predominantly expressed in brown adipose tissue, liver, kidney, duodenum, heart, skeletal muscle, and vascular endothelial cells and is involved in the control of lipoprotein metabolism, fatty acid oxidation, and the cellular uptake of fatty acids. PPAR-gamma is highly expressed in brown and white adipose tissues and. to lesser extent, in large intestine, retina, and some parts of the immune system, and plays a critical role in adipocyte differentiation and fat deposition. PPAR-delta shows a widespread tissue distribution but its regulation and functions are not yet known. Considerable evidence indicates that PPARs (PPAR-a and PPAR-gamma) have beneficial effects in inflammatory diseases, including atherosclerosis, through regulation of cytokine production, adhesion molecule expression on the endothelial cells, fibrinolysis, and modulation of monocyte-derived macrophages. In this review, the general and specific roles of the PPAR isotypes and their implications in the control of vascular inflammation and atherosclerosis are discussed.
引用
收藏
页码:224 / 231
页数:8
相关论文
共 79 条
[1]  
Araki K., 2000, 60 SCI SESS AM DIAB
[2]   Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans - No alteration in adipose tissue of obese and NIDDM patients [J].
Auboeuf, D ;
Rieusset, J ;
Fajas, L ;
Vallier, P ;
Frering, V ;
Riou, JP ;
Staels, P ;
Auwerx, J ;
Laville, M ;
Vidal, H .
DIABETES, 1997, 46 (08) :1319-1327
[3]   Peroxisome proliferator-activated receptor (PPAR)-γ expression in human vascular smooth muscle cells:: Inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-γ activator troglitazone [J].
Benson, S ;
Wu, J ;
Padmanabhan, S ;
Kurtz, TW ;
Pershadsingh, HA .
AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (01) :74-82
[4]  
Bisgaier CL, 1998, J LIPID RES, V39, P17
[6]   Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12,14-prostaglandin J2 [J].
Bishop-Bailey, D ;
Hla, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) :17042-17048
[7]  
BLANCHARD SG, 2000, 60 SCI SESS AM DIAB
[8]   A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice [J].
Boisvert, WA ;
Santiago, R ;
Curtiss, LK ;
Terkeltaub, RA .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) :353-363
[9]   Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice [J].
Boring, L ;
Gosling, J ;
Chensue, SW ;
Kunkel, SL ;
Farese, RV ;
Broxmeyer, HE ;
Charo, IF .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (10) :2552-2561
[10]   Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat [J].
Braissant, O ;
Foufelle, F ;
Scotto, C ;
Dauca, M ;
Wahli, W .
ENDOCRINOLOGY, 1996, 137 (01) :354-366